Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 30;14(13):3230. doi: 10.3390/cancers14133230

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Clinical trials of different dual-targeting CAR T-cell therapies. Different dual CAR strategies have been translated into six clinical trials on Tandem Bi-CART targeting CD19/CD20, CD19/CD22, and BCMA/CD38; four trials on cocktail/sequential infusion of two separate Si-CAR-T products on CD19/CD22 Si-CART and BCMA/CD19 Si-CART; three trials on Loop Bi-CART targeting CD19/CD22; two trials on bicistronic Bi-CART targeting CD19/CD22; and two trials on CD19/CD22 Bi-CART produced by co-transduction of two separate vectors. The bar chart was created using Microsoft^® Excel^® version 2111. Abbreviations: BCMA, B cell maturation antigen; Bi-CART, bispecific chimeric antigen receptor T cells; Bi-CAR-T, bispecific chimeric antigen receptor T-cell; CAR, chimeric antigen receptor; CAR-T, chimeric antigen receptor T cell(s); Si-CART, single-targeted chimeric antigen receptor T cells; Si-CAR-T, single-targeted chimeric antigen receptor T-cell.